Because TET2 inhibition impairs PD-L1 transcription and confers tumor resistance to immunotherapy 29, we investigated whether augmenting TET activity through CPS1 inhibition enhances programmed death-ligand 1 (PD-L1) expression. The gene discussed is CPS1; the disease is neoplasm.